Alert for Atherosclerotic Cardiovascular Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Atherosclerotic Cardiovascular Disease+1 MoreAlert - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is focused on the feasibility of implementing an electronic alert system to notify patients and doctors of high LDL-C values. 400 patients will be randomly selected to either receive notifications or not.

Eligible Conditions
  • Atherosclerotic Cardiovascular Disease
  • Mixed Hyperlipidemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 90 days

90 days
Change in LDL-C level at next follow-up laboratory test
frequency of prescription of appropriate LDL-lowering therapy

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

No Alert
1 of 2
Alert
1 of 2

Active Control

Experimental Treatment

400 Total Participants · 2 Treatment Groups

Primary Treatment: Alert · No Placebo Group · N/A

Alert
Behavioral
Experimental Group · 1 Intervention: Alert · Intervention Types: Behavioral
No AlertNoIntervention Group · 1 Intervention: No Alert · Intervention Types:
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alert
2013
N/A
~4910

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 90 days

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,480 Previous Clinical Trials
9,735,429 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The person was admitted to the BWH Cardiovascular Medicine Service with a diagnosis of ASCVD.
An individual's most recent LDL-C value greater than 80 mg/dL is a predictor of heart disease.
People who are taking a statin medication, but are not taking an ezetimibe or PCSK9 inhibitor medication, may be eligible to participate in the study.
The patient is already receiving therapy with a PCSK9 inhibitor.